HK1213800A1 - 類毒素、組合物及相關方法 - Google Patents

類毒素、組合物及相關方法 Download PDF

Info

Publication number
HK1213800A1
HK1213800A1 HK16101854.5A HK16101854A HK1213800A1 HK 1213800 A1 HK1213800 A1 HK 1213800A1 HK 16101854 A HK16101854 A HK 16101854A HK 1213800 A1 HK1213800 A1 HK 1213800A1
Authority
HK
Hong Kong
Prior art keywords
methods
compositions
toxoid
related methods
inactivating
Prior art date
Application number
HK16101854.5A
Other languages
English (en)
Chinese (zh)
Inventor
Steven HAUSER
Original Assignee
Sanofi Pasteur, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur, Inc. filed Critical Sanofi Pasteur, Inc.
Publication of HK1213800A1 publication Critical patent/HK1213800A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK16101854.5A 2013-03-15 2014-03-14 類毒素、組合物及相關方法 HK1213800A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790423P 2013-03-15 2013-03-15
US61/790,423 2013-03-15
PCT/US2014/029035 WO2014144567A2 (en) 2013-03-15 2014-03-14 Toxoid, compositions and related methods

Publications (1)

Publication Number Publication Date
HK1213800A1 true HK1213800A1 (zh) 2016-07-15

Family

ID=50489430

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101854.5A HK1213800A1 (zh) 2013-03-15 2014-03-14 類毒素、組合物及相關方法

Country Status (13)

Country Link
US (2) US20160045586A1 (https=)
EP (1) EP2968507A2 (https=)
JP (1) JP2016516721A (https=)
KR (1) KR20150133770A (https=)
CN (1) CN105338997A (https=)
AR (1) AR095669A1 (https=)
AU (1) AU2014228956A1 (https=)
BR (1) BR112015023332A2 (https=)
CA (1) CA2907154A1 (https=)
HK (1) HK1213800A1 (https=)
SG (1) SG11201507608PA (https=)
TW (1) TWI624474B (https=)
WO (1) WO2014144567A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
JP6691477B2 (ja) * 2013-06-14 2020-04-28 サノフィ パストゥール インコーポレイテッド クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法
BR112017024443A2 (pt) * 2015-05-15 2018-10-23 Sanofi Pasteur Inc métodos para imunização contra clostridium difficile
US11154605B2 (en) 2017-06-09 2021-10-26 Hipra Scientific, S.L.U. Vaccine comprising Clostridium toxoids
US10096313B1 (en) * 2017-09-20 2018-10-09 Bose Corporation Parallel active noise reduction (ANR) and hear-through signal flow paths in acoustic devices
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
JP2024546686A (ja) * 2021-12-06 2024-12-26 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー 癌を治療するための組成物及び方法
CN120615016A (zh) 2023-02-02 2025-09-09 葛兰素史克生物有限公司 免疫原性组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US5610023A (en) * 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
EP2305293A3 (en) * 1997-10-20 2013-11-06 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6669520B2 (en) 2001-09-19 2003-12-30 United Microelectronics Corp. Method of fabricating an LC panel
MX2010001054A (es) 2007-07-26 2010-04-21 Sanofi Pasteur Ltd Composiciones adyuvantes antigenicas y metodos.
HUE037932T2 (hu) 2007-09-14 2018-09-28 Sanofi Pasteur Biologics Llc Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók
GB201011968D0 (en) * 2010-07-16 2010-09-01 Secr Defence Toxoiding method

Also Published As

Publication number Publication date
US20180028637A1 (en) 2018-02-01
SG11201507608PA (en) 2015-10-29
JP2016516721A (ja) 2016-06-09
KR20150133770A (ko) 2015-11-30
US20160045586A1 (en) 2016-02-18
CA2907154A1 (en) 2014-09-18
WO2014144567A2 (en) 2014-09-18
AR095669A1 (es) 2015-11-04
WO2014144567A3 (en) 2014-12-04
TW201514197A (zh) 2015-04-16
AU2014228956A1 (en) 2015-10-08
CN105338997A (zh) 2016-02-17
BR112015023332A2 (pt) 2017-08-22
TWI624474B (zh) 2018-05-21
EP2968507A2 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
HK1213800A1 (zh) 類毒素、組合物及相關方法
EP4494650A3 (en) Vaccine compositions having improved stability and immunogenicity
AU2014241199A8 (en) Compositions and methods for enhancing plant growth
WO2016094837A3 (en) Anti-c10orf54 antibodies and uses thereof
MX2011007983A (es) Composiciones de polimero que contienen absorbedores de ir nanoparticulas.
WO2014201044A3 (en) Plant growth-promoting microorganisms and methods of use thereof
HK1208216A1 (en) Drug-conjugates, conjugation methods, and uses thereof
WO2014097099A3 (en) Glycoconjugation process
PH12019500989A1 (en) Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
WO2013006055A8 (en) A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
MX361812B (es) Cubierta para ventilador de plástico y ensamble de cono y método.
MX364712B (es) Composiciones sinergicas que comprenden etefona y saflufenacilo o ciclanilida y saflufenacilo.
MX2015010305A (es) Vacuna de combinacion para virus sincitial respiratorio e influenza.
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
PH12018502120A1 (en) Live attenuated alphavirus constructs and methods and uses thereof
TN2015000477A1 (en) A new bacterial lysobacter capsici strain and uses thereof
HK1225744A1 (zh) 制备高纯度的肉毒杆菌毒素神经毒性组分的方法及其应用
NZ709925A (en) Temperature stable cloquintocet-mexyl aqueous compositions
PH12014500175A1 (en) Maize plants having a partially or fully multiplied genome and uses thereof
PH12017501795B1 (en) Pestivirus vaccines for congenital tremors
WO2014205355A3 (en) Compositions and methods for clostridial transformation
MX2016000141A (es) El uso de piridonacarboxamidas seleccionadas o sales de las mismas como sustancias activas contra el estres abiotico de las plantas.
HK1213917A1 (zh) 類霉素、組合物及相關方法
WO2014009204A8 (de) Oxasilacyclen und verfahren zu deren herstellung
BR112012033213B8 (pt) Cassete de expressão, vetor incluindo um construto de arni e método de preparação de uma planta transgênica